CN114929220A - 用于治疗传染病的小分子弗林蛋白酶抑制剂 - Google Patents

用于治疗传染病的小分子弗林蛋白酶抑制剂 Download PDF

Info

Publication number
CN114929220A
CN114929220A CN202080092431.9A CN202080092431A CN114929220A CN 114929220 A CN114929220 A CN 114929220A CN 202080092431 A CN202080092431 A CN 202080092431A CN 114929220 A CN114929220 A CN 114929220A
Authority
CN
China
Prior art keywords
methyl
pyridin
oxy
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092431.9A
Other languages
English (en)
Chinese (zh)
Inventor
K.威尔科克森
C.马帕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bp Asset V Co ltd
Original Assignee
Bp Asset V Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bp Asset V Co ltd filed Critical Bp Asset V Co ltd
Publication of CN114929220A publication Critical patent/CN114929220A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080092431.9A 2019-11-12 2020-11-12 用于治疗传染病的小分子弗林蛋白酶抑制剂 Pending CN114929220A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934407P 2019-11-12 2019-11-12
US62/934,407 2019-11-12
PCT/US2020/060108 WO2021097009A1 (en) 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases

Publications (1)

Publication Number Publication Date
CN114929220A true CN114929220A (zh) 2022-08-19

Family

ID=73793799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092431.9A Pending CN114929220A (zh) 2019-11-12 2020-11-12 用于治疗传染病的小分子弗林蛋白酶抑制剂

Country Status (8)

Country Link
US (1) US20230011571A1 (https=)
EP (1) EP4058021A1 (https=)
JP (1) JP2023503852A (https=)
KR (1) KR20220104744A (https=)
CN (1) CN114929220A (https=)
AU (1) AU2020382819A1 (https=)
CA (1) CA3157892A1 (https=)
WO (1) WO2021097009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022961A2 (pt) 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152716A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
CN107441094A (zh) * 2017-08-08 2017-12-08 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CN112384509A (zh) * 2018-05-11 2021-02-19 葛兰素史密斯克莱知识产权发展有限公司 弗林蛋白酶抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
EP2478766A3 (en) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
WO2014152716A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
CN107441094A (zh) * 2017-08-08 2017-12-08 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CN112384509A (zh) * 2018-05-11 2021-02-19 葛兰素史密斯克莱知识产权发展有限公司 弗林蛋白酶抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAUN E等: "Furin-mediated protein processing in infectious diseases and cancer", CLINICAL & TRANSLATIONAL IMMUNOLOGY, vol. 8, no. 8, 1 January 2019 (2019-01-01), pages 1 - 19 *
BRUNO, RAMOS-MOLINA等: "Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays", BIOCHEMICAL PHARMACOLOGY, vol. 96, no. 2, 21 May 2015 (2015-05-21), pages 107 - 118 *
CLARK M J等: "GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein", CELL CHEMICAL BIOLOGY, vol. 23, no. 4, 21 April 2016 (2016-04-21), pages 443 - 452, XP029518402, DOI: 10.1016/j.chembiol.2016.03.010 *
WISPELAERE M D等: "Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein", CELL CHEMICAL BIOLOGY, vol. 25, no. 8, 1 August 2018 (2018-08-01), pages 1006 - 1016 *

Also Published As

Publication number Publication date
US20230011571A1 (en) 2023-01-12
CA3157892A1 (en) 2021-05-20
KR20220104744A (ko) 2022-07-26
EP4058021A1 (en) 2022-09-21
JP2023503852A (ja) 2023-02-01
WO2021097009A1 (en) 2021-05-20
AU2020382819A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CN114524821B (zh) 螺旋吡咯烷衍生的抗病毒药物
US12577240B2 (en) Antiviral heteroaryl ketone derivatives
EP3262049B1 (en) Tyk2 inhibitors and uses thereof
KR20220145325A (ko) Irak 분해제 및 이의 용도
UA126394C2 (uk) Похідні бензоксазолу як імуномодулятори
CN102770435B (zh) 吡唑并嘧啶类化合物及其作为pde10抑制剂的用途
TW200817403A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN105732635A (zh) 一类Toll样受体7激动剂
CN115038688A (zh) Usp30抑制剂及其用途
TWI851890B (zh) 抗病毒性1,3-二氧代茚化合物
WO2015169180A1 (en) Substituted piperazine compounds and methods and use thereof
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
CN110291090A (zh) 作为新型jak激酶抑制剂的双环胺
WO2025014877A2 (en) Triazolo wrn inhibitors
CN117396474A (zh) 血浆激肽释放酶抑制剂
CN105399756B (zh) Btk抑制剂及其用途
CN114929220A (zh) 用于治疗传染病的小分子弗林蛋白酶抑制剂
CN117836270A (zh) Usp30抑制剂及其用途
CN117396469A (zh) 血浆激肽释放酶的抑制剂
KR20210005569A (ko) Rsv에 대한 활성을 갖는 헤테로방향족 화합물
CN113768935B (zh) 免疫疾病的预防剂和/或治疗剂
CA3115595A1 (en) Further heteroaromatic compounds having activity against rsv
AU2017294983A1 (en) Inhibitors of tryptophan 2,3-dioxygenase
CN118047800A (zh) 一类白介素-1受体相关激酶的双功能嵌合体杂环化合物及其制备方法和用途
CA3259558A1 (en) COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220819

RJ01 Rejection of invention patent application after publication